1 gct9701 please see brief summary and accompanying full prescribing information on slides 29-32....
TRANSCRIPT
1GCT9701
Please see Brief Summary and accompanying full Prescribing Information on slides 29-32. Indications may vary between countries. This piece is for promotional use with healthcare professionals upon local regulatory approval in your particular country. Each CPO is responsible for ensuring that this material is reviewed and approved in accordance with the local NP4 approval process.
UPDATE IN THE MANAGEMENT OF
NEUROENDOCRINE TUMOURS
2GCT9701
NEUROENDOCRINE TUMOUR
(NET) OVERVIEW
3GCT9701
NEUROENDOCRINE TUMOURS (NETs)
• Arise from cells of the neuroendocrine system1
• Most common type are gastroenteropancreaticNETs (GEP-NETs) of the gastrointestinal (GI) system2
• Generally small (< 1 cm in diameter) and slow-growing3
• Have metastatic potential3*Age-adjusted annual incidence per 100,000 in the 2000 US population; from the SEER 17 registry
GI SYSTEM (2.89)
Pancreas (0.32)
Liver (0.04)
Stomach (0.30)
Duodenum (0.19)
Jejunum/ileum
(0.67)
Cecum (0.16)
Appendix (0.15)
Colon (0.20)
Rectum (0.86)
LUNG (1.35)
THYMUS (0.02)
OTHER/UNKNOWN(0.74)
SITE OF PRIMARY TUMOUR2
(Incidence per 100,000)*
1. Ramage JK, Davies AH, Ardill J, et al. Gut. 2005;54:iv1-iv16. 2. Yao JC, Hassan M, Phan A, et al. J Clin Oncol. 2008;26:3063-3072. 3. Kufe DW, Pollock RE, Weichselbaum RR, et al. eds. Holland-Frei Cancer Medicine, 6th ed. Hamilton (ON): BC Decker; 2003.
4GCT9701
NETs ARE MORE PREVALENTTHAN MANY TUMOURS OF THE GI SYSTEM
1. National Cancer Institute. SEER Cancer Statistics Review 1975-2004. Complete and Limited-Duration Cancer Prevalence Estimates. http://seer.cancer.gov/csr/1975_2004/results_merged/topic_prevalence.pdf. Accessed 28 March 2011.
2. Yao JC, Hassan M, Phan A, et al. J Clin Oncol. 2008;26:3063-3072.
5GCT9701
ASYMPTOMATICNETs
• Also called nonfunctioning NETs
• More common than symptomatic NETs1
• Do not cause clinical syndromes2
• Usually present due to mass effects and/or metastatic disease1,2
A LACK OF DISTINCT SYMPTOMS MAY DELAY NET DIAGNOSIS
1. Modlin IM, Öberg K, Chung DC, et al. Lancet Oncol. 2008;9:61–72. 2. Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Endocr Relat Cancer. 2010;17:R173–R193.3. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Gastroenterology. 2005;128:1717–1751.
NETs ARE TYPICALLY PRESENT FOR 5–7 YEARS PRIOR TO DIAGNOSIS1
SYMPTOMATICNETs
• Also called functioning NETs
• Release bioactive substances to the bloodstream2
• May cause paraneoplastic disease2
• Symptoms may mimic other conditions1 (e.g. symptomatic GEP-NETs typically produce flushing and diarrhoea)3
6GCT9701
NEARLY HALF OF ALL NETs ARE ADVANCED AT DIAGNOSIS
Yao JC, Hassan M, Phan A, et al. J Clin Oncol. 2008;26:3063-3072.
*Includes the 78.4% of NET patients in the SEER 17 registry with staging information available at diagnosis.
7GCT9701
ADVANCED DISEASE IS ASSOCIATED WITH POORER 5-YEAR SURVIVAL
Yao JC, Hassan M, Phan A, et al. J Clin Oncol. 2008;26:3063-3072.
8GCT9701
WITHOUT TREATMENT, THE MAJORITY OF PATIENTS WITH ADVANCED MIDGUT NETs WILL PROGRESS
WITHIN 1 YEAR
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
9GCT9701
SOMATOSTATIN SIGNALLING
10GCT9701
• The majority of NETs express somatostatin receptors (SSTRs)2
• Approximately 80% of GEP-NETs express the SSTR2 subtype3
POTENTIAL THERAPEUTIC TARGET:SOMATOSTATIN SIGNALLING IN NETs
• Somatostatin signalling:1
―Decreases hormone secretion and controls symptoms
―Promotes cell death (apoptosis)
―Inhibits cell growth
1. Öberg KE, Reubi J-C, Kwekkeboom DJ, Krenning EP. Gastroenterology. 2010;139:742-753. 2. Hicks RJ. Cancer Imaging. 2010;10:S83-S91. 3. Kulaksiz H, Eissele R, Rössler D, et al. Gut. 2002;50:52-60.
11GCT9701
DIRECT AND INDIRECT ANTIPROLIFERATIVE EFFECTS OF SOMATOSTATIN SIGNALLING
SOMATOSTATIN RECEPTOR ACTIVATION
Indirect antiproliferative effect
Binding of somatostatin receptors on tumour cells
Inhibition of growth factor
effects
Inhibition of cell cycle
Pro-apoptotic effect
Systemic effect
Inhibition of growth factor and trophic hormones
Immune system
modulation
Inhibition of angiogenesis
Direct antiproliferative effect
Susini C, Buscail L. Ann Oncol. 2006;17:1733-1742.
12GCT9701
DELAYING THE PROGRESSION
OF NEUROENDOCRINETUMOURS
13GCT9701
PROMID: PIVOTAL PHASE III TRIAL DEMONSTRATING TUMOUR CONTROL BY SANDOSTATIN LAR
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
• PROMID: Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine MIDgut Tumors
• Phase III, randomised, double-blind, placebo-controlled trial
• Designed to evaluate the antiproliferative effects of the somatostatin analogue Sandostatin® (octreotide) LAR® 30 mg
• Conducted at 18 centres in Germany (2001–2008)
14GCT9701
PROMID DESIGN AND ENDPOINTS
Primary Endpoint – TTP (defined as time to tumour progression or time to tumour-related
death)
Secondary Endpoints – Survival time– Quality of life– Clinical and biochemical response (in patients with symptomatic disease)– Safety
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
Randomised Patients (N = 85)• Treatment naïve• Karnofsky status > 60%• Tumour criteria
– Midgut origin– Well-differentiated histology– Locally inoperable or metastatic– Measurable (CT/MRI)
• Symptomatic or asymptomatic
Ran
dom
isati
on
(1:1
)
Sandostatin LAR 30 mg(N = 42) IM every 28 days
Placebo (N = 43)IM every 28 days
Treatment until tumour progression
or death
15GCT9701
PROMID PATIENT CHARACTERISTICS AT BASELINE
Sandostatin LAR 30 mg
(N = 42)
Placebo(N = 43)
Total(N = 85)
Median age, years (range) 63.5 (38–79) 61 (39–82) 62 (38–82)
Male (%) 20 (47.6) 23 (53.5) 43 (50.6)
Months since diagnosis (range) 7.5 (0.8–271.7) 3.3 (0.8–109.4) 4.3 (0.8–271.7)
Karnofsky performance status > 80% (%)
35 (83.3) 38 (88.4) 73 (85.9)
Symptomatic disease (%) 17 (40.5) 16 (37.2) 33 (38.8)
Resection of primary tumour (%) 29 (69.1) 27 (62.8) 56 (65.9)
Ki-67 up to 2% (%) 41 (97.6) 40 (93.0) 81 (95.3)
Octreoscan Positive (%)
Negative (%)
32 (76.2)4 (9.5)
31 (72.1)6 (14.0)
63 (74.1)10 (11.8)
Liver involvement ≤ 10% (%)
> 10% (%)
32 (76.2)10 (23.8)
32 (74.4)11 (25.6)
64 (75.3)21 (24.7)
Chromogranin A Elevated (%)
Not elevated (%)
26 (61.9)15 (35.7)
30 (69.8) 12 (27.9)
56 (65.9)27 (31.8)
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
16GCT9701
• More than double the median TTP (14.3 months with Sandostatin LAR 30 mg vs 6.0 months with placebo; P = 0.000072)
• 66% reduction in the risk of disease progression (HR = 0.34)
SANDOSTATIN LAR 30 MG SIGNIFICANTLYPROLONGS TTP* OVER PLACEBO
Results seen in the Sandostatin LAR 30 mg group, compared with placebo
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
*TTP: Time to tumour progression or tumour-related death
17GCT9701
• Symptomatic: HR = 0.23(95% CI: 0.09–0.57)
• Asymptomatic: HR = 0.25(95% CI: 0.10–0.59)
THE MAJORITY OF PATIENTS IN THE PROMID TRIAL WERE ASYMPTOMATIC
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
Sandostatin LAR 30 mg prolonged TTP over placebo, regardless of symptomatic or asymptomatic disease
18GCT9701
MAJORITY OF PATIENTS WHO RECEIVED SANDOSTATIN LAR 30 MG
ACHIEVED STABLE DISEASE AT 6 MONTHS*
Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
*As defined by WHO criteria
P = 0.0079
19GCT9701
SANDOSTATIN LAR IS GENERALLY WELL TOLERATED1
OBSERVED SAFETY FINDINGS IN THE PROMID TRIALWERE CONSISTENT WITH THOSE SEEN IN PREVIOUS
STUDIES OF SANDOSTATIN LAR IN PATIENTS WITH NETs1-3
Adverse events in PROMID3 Sandostatin LAR 30 mg(N = 42)
Placebo(N = 43)
Serious adverse event 11 10
Most frequent serious adverse events
Gastrointestinal tract 6 8
Haematopoietic system 5 1
General health status (fatigue, fever) 8 2
Adverse event causing discontinuation 5 0
1. Sandostatin LAR Basic Prescribing Information. Novartis Pharma AG. 20 May 2010.2. Rubin J, Ajani J, Schirmer W, et al. J Clin Oncol. 1999;17:600-606.3. Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663.
20GCT9701
GUIDELINES
CPO: Please provide your local guidelines here
21GCT9701
MANAGEMENT OFSYMPTOMATIC GEP-NETs
22GCT9701
GEP-NET SYMPTOMS CAN HAVE IMMEDIATE AND LONG-TERM CONSEQUENCES
1. Creutzfeldt W. World J Surg. 1996;20:126-131.2. McCormick D. Gastroenterol Nurs. 2002;25:105-113.3. Zuetenhorst JM, Taal BG. Oncologist. 2005;10:123-131.
• Diarrhoea and flushing are the two most common GEP-NET symptoms.1
– Patients may have up to 30 stools per day, accompanied by pain.2
– Flushing is an outwardly visible sign of the disease.2
• Potentially life-threatening dehydration, hypotension, arrhythmias, and unconsciousness can develop from early symptoms, like diarrhoea and flushing.3
COMMON GEP-NET SYMPTOMS1
23GCT9701
REDUCTION IN THE FREQUENCY OF DIARRHOEA WITH SANDOSTATIN LAR 20 MG
Data on file. Novartis Pharma AG.
IN FUNCTIONAL CARCINOID PATIENTS:
24GCT9701
REDUCTION IN THE FREQUENCY OF FLUSHING EPISODES WITH SANDOSTATIN LAR 20 MG
Data on file. Novartis Pharma AG.
IN FUNCTIONAL CARCINOID PATIENTS:
25GCT9701
SUPPRESSION OF 5-HIAA* LEVELS WITH SANDOSTATIN LAR 20 MG
Rubin J, Ajani J, Schirmer W, et al. J Clin Oncol. 1999;17:600-606.
*5-hydroxyindoleacetic acid: serotonin metabolite used to assess tumour hormone secretion** 20 and/or 24 weeks
IN FUNCTIONAL CARCINOID PATIENTS:
26GCT9701
SANDOSTATIN LAR DOSING
Sandostatin LAR Basic Prescribing Information. Novartis Pharma AG. 20 May 2010.
IN PATIENTS WITH ADEQUATE SYMPTOM CONTROL WITH SANDOSTATIN SC
• Initiate Sandostatin LAR 20 mg every 4 weeks
• Continue Sandostatin SC for 2 weeks after initiating Sandostatin LAR
• After 3 months, assess need for dose adjustments based on symptomatic response
TUMOUR CONTROL
SYMPTOM CONTROL
• Sandostatin LAR 30 mg IM every 4 weeks
• Continue treatment in the absence of tumour progression
SANDOSTATIN IS AVAILABLE IN A SUBCUTANEOUS (SC) FORMULATION FOR BREAKTHROUGH
SYMPTOMS
27GCT9701
SUMMARY
1. National Cancer Institute. SEER Cancer Statistics Review 1975-2004. Complete and Limited-Duration Cancer Prevalence Estimates. http://seer.cancer.gov/csr/1975_2004/results_merged/topic_prevalence.pdf. Accessed 28 March 2011.
2. Yao JC, Hassan M, Phan A, et al. J Clin Oncol. 2008;26:3063-3072. 3. Kufe DW, Pollock RE, Weichselbaum RR, et al. eds. Holland-Frei Cancer Medicine, 6th ed. Hamilton (ON): BC Decker; 2003.4. Rinke A, Müller HH, Schade-Brittinger C, et al. J Clin Oncol. 2009;27:4656–4663. 5. Öberg KE. J Clin Oncol. 2009;27:4635-4636.6. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumors. V.1.2011.
• The randomised, placebo-controlled phase III PROMID trial demonstrated that:
– Sandostatin LAR 30 mg is the only somatostatin analogue to significantly prolong TTP in patients with advanced midgut NETs.4,5
– Significantly more patients achieved stable disease with Sandostatin LAR than with placebo.4
• Sandostatin LAR is the first and only somatostatin analogue proven to have an antiproliferative effect on advanced midgut NETs.5
• Updated treatment guidelines now recommend Sandostatin LAR for early
tumour control in patients with advanced midgut NETs or unknown primary tumour location.6
• NETs are more prevalent than many other tumours of the GI system.1,2
• Although most NETs are small tumours, they can progress to metastatic disease, which has implications for survival.2,3
• Nearly half of all NET patients are diagnosed with advanced disease.2
28GCT9701
SUMMARY (CONTINUED)
• The most common symptoms are diarrhoea and flushing.1
• Potentially life-threatening dehydration, hypotension, arrhythmias, and unconsciousness can develop from early symptoms, like diarrhoea and flushing.2
• In functional carcinoid patients, Sandostatin LAR has been proven to reduce:
– The frequency of diarrhoea and flushing episodes.3,4
– 5-HIAA levels.4
• Sandostatin is available in a subcutaneous (SC) formulation for breakthrough symptoms.
1. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Gastroenterology. 2005;128:1717–1751.2. Zuetenhorst JM, Taal BG. Oncologist. 2005;10:123-131.3. Data on file. Novartis Pharma AG.4. Rubin J, Ajani J, Schirmer W, et al. J Clin Oncol. 1999;17:600-606.
29GCT9701
FULL PRESCRIBING INFORMATION
CPO: Please provide your local full Prescribing Information
30GCT9701
BRIEF SUMMARY
Important note: Before prescribing, consult full prescribing information.
Presentation: Octreotide acetate. Vials containing 10 mg, 20 mg or 30 mg octreotide free peptide supplied as powder (microspheres) for suspension for injection together with a prefilled syringe (solvent for parenteral use), containing: sodium carboxymethylcellulose 12.5 mg, mannitol 15 mg; water for injection qs ad 2.5 mL; two needles [40 mm (1.5 inch), 19 gauge]. Sandostatin® LAR® suspension contains less than 1 mmol (23 mg) of sodium per dose, i.e. essentially ‘sodium-free’.
Indication: Acromegaly: in patients who are adequately controlled on SC treatment with Sandostatin; in patients in whom surgery or radiotherapy is inappropriate or ineffective; in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastro-entero-pancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, insulinomas, GRFomas. Treatment of patients with advanced neuroendocrine tumours of the midgut or unknown primary tumour location.
Dosage: 10 to 30 mg every 4 weeks, administered as a deep intragluteal injection.
31GCT9701
BRIEF SUMMARY (CONTINUED)
Contraindications: Known hypersensitivity to octreotide or to any of the excipients.
Warnings/Precautions: Dose adjustments of drugs such as beta-blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, may be necessary; caution in patients with insulinomas; diabetes mellitus thyroid function should be monitored in patients receiving prolonged treatment with octreotide. Periodic examination of gallbladder; monitoring of vitamin B12 levels in patients who have a history of vitamin B12 deprivation; caution in patients with pregnancy, patients should be advised to use adequate contraception if necessary. Patients should not breast-feed during Sandostatin LAR treatment.
Interactions: Impaired intestinal absorption of ciclosporin, cimetidine; increased bioavailability of bromocriptine. Caution with concomitant use of drugs mainly metabolised by CYP3A4 and which have a low therapeutic index.
32GCT9701
BRIEF SUMMARY (CONTINUED)
Adverse reactions: Very common (≥1/10) adverse drug reactions are: diarrhoea, abdominal pain, nausea, constipation, flatulence, headache, cholelithiasis, hyperglycaemia, and injection-site localised pain. Common (≥1/100, <1/10) adverse drug reactions are: dyspepsia, vomiting, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces, dizziness, hypothyroidism, thyroid dysfunction (e.g. decreased thyroid stimulating hormone [TSH], decreased Total T4, and decreased Free T4), cholecystitis, biliary sludge, hyperbilirubinaemia, hypoglycaemia, impairment of glucose tolerance, anorexia, elevated transaminase levels, pruritus, rash, alopecia, dyspnoea, and bradycardia. Uncommon (≥1/1000, <1/100) adverse drug reactions are: dehydration, and tachycardia. Post-marketing the following adverse reactions have been reported: anaphylaxis, allergy/hypersensitivity reactions, urticaria, acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice, arrhythmia, increased alkaline phosphatase levels, and increased gamma glutamyl transferase levels.
Packs and prices: Country specific.
Legal classification: Country specific.